![[img]](https://epub.uni-regensburg.de/style/images/fileicons/application_pdf.png) | Lizenz: Creative Commons Namensnennung 4.0 International PDF - Veröffentlichte Version (2MB) |
- URN zum Zitieren dieses Dokuments:
- urn:nbn:de:bvb:355-epub-768757
- DOI zum Zitieren dieses Dokuments:
- 10.5283/epub.76875
Zusammenfassung
In recent years, early use of highly effective disease modifying immunotherapies in relapsing-remitting multiple sclerosis (RRMS) demonstrated superior efficacy in preventing disability progression. For this study, we investigated ocrelizumab as first line therapy of RRMS in a monocentric, retrospective study. In our outpatient clinic, ocrelizumab was administered as first-line therapy in 33 ...
Nur für Besitzer und Autoren: Kontrollseite des Eintrags
Downloadstatistik